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Abstract 
Survey and interview-based findings from the Consumer Study of the Australian Genetic 
Discrimination Project (GDP) are reported. These involve perceptions and experiences of 
clinical genetics clients regarding coercion to undertake genetic testing and insurance and 
employment-related issues. Genetic discrimination is defined as the differential treatment of 
asymptomatic individuals because of actual or presumed genetic differences. Eligible adults 
(n=2667) who had requested predictive testing for designated mature-onset conditions, 1998 
to 2003, were surveyed; 951/1185 respondents met asymptomatic inclusion criteria. 
Neurological disorders and familial cancers were relevant to the majority. Sources of 
coercion, where reported, included family members, doctors, geneticists/counsellors and life 
insurers. Insurance and employment related issues were raised; some respondents reported 
avoiding or being advised not to apply for life insurance. Interview data further elucidate 
context and impact of coercion and/or negative treatment. The experiences of respondents 
where neurological conditions were relevant differed from others. Implications of the study 
are discussed.  
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Introduction 
Consumer perceptions and experiences regarding human genetic technologies and 
associated legal, ethical and social issues are topical issues in Australia as elsewhere 
(Australian Law Reform Commission & Australian Health Ethics Committee of the National 
Health & Medical Research Council NHMRC (ALRC/AHEC) 2003; Geller 2002; Petersen & 
Bunton 2002). A key ethical, legal and social concern associated with the rapid development 
of genetic testing technology has been the potential for genetic discrimination, defined as the 
differential treatment of asymptomatic individuals or their relatives on the basis of real or 
assumed genetic differences or characteristics (Otlowski et al 2002; Geller 2002; Billings et 
al. 1992). Although such differential treatment can potentially be to the advantage or 
disadvantage of an individual, most concerns have related to negative treatment.  
Information about a person’s genetic makeup, characteristics or health can be suggested 
from their family history or from the results of a genetic test. There are currently over 1300 
conditions for which genetic tests are available in clinical settings and a further 300 are being 
developed in research contexts (http://www.genetests.org). Within the Australian context, 
more than 220 gene tests are now available; in addition, tests can be accessed 
internationally (ALRC/AHEC 2003). Such tests can be used to diagnose genetic conditions, 
to screen population groups for genetic risks or predispositions and to identify carriers of 
faulty genes in the context of reproductive risk. Genetic tests can also be utilised to assess a 
person’s potential for developing conditions in the future through identifying mutations in 
genes that cause or predispose individuals to illness (Haan 2003); such tests are referred to 
as pre-symptomatic or predictive tests depending upon whether the result can indicate 
definite development of a future condition or an increased risk of developing such a condition 
in the future, respectively.  
Identifying potential characteristics of an individual’s future health through predictive genetic 
testing when the person is otherwise healthy and free of any symptoms of the relevant 
genetic condition, is potentially beneficial in many ways. It can enable early detection, 
treatment and preventive strategies regarding particular genetic conditions and assist in 
people’s choices and life planning where there is no treatment or prevention. However, 
predictive testing can also be associated with the potential for individuals to be treated 
differently based on what people know or even wrongfully assume about the tested 
individual’s genetic characteristics as a result of them being tested. Such differential 
treatment can constitute genetic discrimination. There are many genetic conditions that can 
now be predictively tested for and which are therefore associated with the potential for 
genetic discrimination; these include neurodegenerative conditions like Huntington disease 
(HD) or familial Alzheimer disease and familial cancers such as inherited predisposition to 
breast or bowel cancers1.  
Reports of negative genetic discrimination have been published in Australia (ALRC/AHEC 
2003, Barlow-Stewart & Keays 2001), the United States (Billings et al. 1992; Geller et al. 
2002, 1996; Hall et al. 2005), Canada (Lemmens et al. 2004), the United Kingdom (Low et al. 
1998) and Europe (Hendricks 1997; Sandberg 1995). Such reports have been in regard to 
alleged negative treatment in organisational or institutional contexts like health, life and 
disability insurance and employment (Otlowski 2005, 2002, 2001); clinical, health care and 
blood bank services; fertility and adoption services and intake to armed services (Barlow-
Stewart & Keays 2001; Billings et al. 1992; Geller et al. 2002; Lapham et al. 1996). 
Discussion of insurance within the Australian context relates mainly to life, rather than health, 
insurance, as the latter is community-rated in Australia, similar to Canada and the United 
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Kingdom; this is unlike the United States where individually-rated health insurance 
significantly increases the potential for genetic discrimination (ALRC/AHEC 2003; Barash 
2000). Insurers in Australia are also legally entitled to discriminate between applicants 
because of exemptions under the Commonwealth Disability Discrimination Act (1992) (Cth), 
provided their decisions can be substantiated actuarially (Otlowski 2001).   
Negative treatment can also occur in informal or social contexts like families or interpersonal 
relationships where legal analysis may be less relevant (Geller et al. 2002; Lemke 2005; 
Treloar et al. 2004). In such instances, for example where the reproductive fitness of a 
person with a known genetic risk is called into question, negative treatment can be based on 
prejudicial attitudes and social stigma regarding people perceived to have ‘bad blood’ 
(Lemke 2005; Otlowski 2005). Experiencing genetic discrimination, according to Geller et al 
(2002, p.256), can result in a range of personal and psychological reactions for both the 
individual and their close others including ‘loss of self-esteem, alienation from family 
members and others, and alterations in family dynamics’. Findings from a recent Canadian 
study undertaken by Bombard et al. (2007) describe some of the strategies that individuals 
have adopted in order to cope with and manage the risk that they may encounter genetic 
discrimination if they are found to have the positive Huntington disease mutation. Such 
strategies, like ‘keeping low’, avoiding both genetic testing and insurance applications or 
engaging in highly selective disclosure of their genetic risk or genetic test information have 
now been reported in several studies (Bombard et al. 2007; Geller et al. 1996; Peterson et al. 
2002; Taylor 2004). This suggests that, in spite of ongoing societal, ethical and legal 
concerns about the potential for genetic discrimination to occur, it has for many individuals 
become a real threat and one that is significantly impacting upon their behaviour.  
Within the Australian context, anecdotal accounts and case studies of genetic discrimination 
have been reported for some years (for example, Barlow-Stewart & Keays 2001; Taylor 
1998). In the 2001 study by Barlow-Stewart and Keays, 48 cases were identified, mostly in 
regard to access to life insurance as well as some alleged discrimination in employment. 
Partially as a result of this research, genetic discrimination became a focus of the national 
inquiry in Australia into The Protection of Human Genetic Information conducted jointly by the 
ALRC and the AHEC (ALRC/AHEC 2003). The report from the inquiry entitled Essentially 
Yours, provided a comprehensive overview of the issue of genetic discrimination as well as 
recommendations which included the establishment of a dedicated body in Australia to 
investigate and monitor this and other genetics-related issues in Australia in an ongoing way. 
In 2005, the Commonwealth Government established a Human Genetics Advisory 
Committee under the auspices of the National Health and Medical Research Council to 
advise government regarding genetic issues, genetic health services and related issues 
(Commonwealth Department of Health and Ageing 2005). Whilst these developments have 
been very significant within the Australian context, the issue of genetic discrimination has not 
been empirically investigated in Australia until recently (Taylor et al. 2004).  
The potential for people to experience genetic discrimination therefore is now widely 
accepted within Australia and elsewhere (ALRC/AHEC 2003). Information about the risk of 
such discrimination for people on the basis of their family history information or genetic 
testing where undertaken is readily available through genetic support and information 
services in Australia (for example, Centre for Genetics Education (CGE) 2003) while clinical 
genetics services routinely incorporate discussion and advice about life insurance issues into 
pre-test counselling protocols (Human Genetics Society of Australasia (HGSA) 1999).  
Genetic discrimination is a complex concept to investigate (Treloar et al. 2004). While Barash 
(2000) noted that genetic discrimination is a ‘household word’ within the United States due to 
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its potential for broad occurrence involving health insurance, in Australia and countries that 
have community-rather than individual-rated health care, it is a less familiar concept within 
the general community and therefore challenging to investigate empirically. The community-
based rating of health insurance which is legislatively endorsed in Australia may also 
significantly reduce the scope for genetic discrimination to occur in this country when 
compared with others (Otlowski 2001). People’s familiarity with the concept and its relevance 
to them can influence participation rates in community surveys; at the same time explicit use 
of the term ‘genetic discrimination’ within a research context can elicit response bias (Wertz 
2002). Establishing the prevalence of genetic discrimination within any community is also 
potentially difficult as it requires a relevant and defined population from within which a 
proportion of cases of alleged discrimination can be identified (Treloar et al. 2004).  
Finally a key feature of genetic discrimination is that it refers to differential treatment of a 
person who has no manifest symptoms of a condition or disorder and which has occurred 
allegedly on the basis of their genetic characteristics or makeup, either real or assumed. 
Determining that an individual is clinically free of any manifest expression of symptoms of a 
genetic disorder at the time of their alleged negative treatment is theoretically and practically 
difficult. Further, determining that an incident of alleged discriminatory treatment has been 
unequivocally based on a person’s inherent genetic characteristics rather than any other 
factors is also difficult. In spite of these difficulties  and because most accounts to date 
regarding genetic discrimination have been anecdotal, anonymous or case study reports, 
some commentators have questioned whether community concerns about genetic 
discrimination are based more on fear rather than reality (Nowlan 2003; Wertz 2002). Wertz 
(2002 p.496), for example, proposed that fear of discrimination, rather than being well-
founded, may reflect “a ‘genetic dread’ that pervades society”.   
This paper presents selected findings from the Genetic Discrimination Project (GDP)2, a 
comprehensive investigation of genetic discrimination in Australia that has been undertaken 
from 2002 to 2005 (Otlowski, Taylor & Barlow-Stewart 2002). The GDP was of triangulated 
design and comprised several sub-projects. The Consumer Study sub-project aimed to 
survey a targeted sample of asymptomatic clients of clinical genetics services regarding their 
attitudes and experiences of alleged genetic discrimination, to establish the prevalence of 
such discrimination within the sample, to describe the domains within which such incidents 
occurred and, where possible, to follow up and verify the extent to which such incidents could 
be said to constitute genetic discrimination. This paper reports selected survey findings and 
case studies from the Consumer Study which relate to respondent perceptions and 
experiences regarding coercion to undertake testing and insurance and employment issues. 
A forthcoming paper (Taylor et al., 2007, paper in review) describes the consumer survey 
methodology in detail including response bias information and presents other survey findings 
regarding participants’ perceptions about benefits and disadvantages of having genetic 
information, the prevalence of specific incidents of alleged discrimination within the sample 
and the domains in which discrimination had allegedly occurred. Other GDP papers to date 
have reported on methodological challenges associated with investigating genetic 
discrimination (Treloar et al. 2004), the use of genetic test results in insurance underwriting in 
Australia for the period 1999-2003 (Otlowski et al. 2007a), the use of legal remedies for 
pursuing genetic discrimination in Australia (Otlowski et al. 2007b) and a comparison of 
attitudes about genetic issues between consumers in this study and the broader Australian 
community (Barlow-Stewart et al. 2005). Finally, other forthcoming papers will report on 
attitudes and experiences of Australian employers regarding genetic testing in the workplace 
and the verification of incidents of alleged genetic discrimination as reported by consumers.   
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Materials and Methods 
A targeted postal survey was undertaken of eligible clients of 14 Australian clinical and 
research genetic services who agreed to participate in the study (Appendix A). Participating 
services were located in every Australian State and serviced both urban and rural 
communities. Ethical clearance was obtained from all relevant Human Research Ethics 
Committees (HRECs) with regard to the research. 
The Sample 
In keeping with the research focus on differential treatment that was allegedly based on an 
individual’s genetic characteristics, participating services identified from their records 
asymptomatic adults aged 18 years and over who had requested, or inquired about, 
predictive genetic testing for a range of mature-onset genetic conditions, during the period 
January 1998 to December 2003. The genetic conditions included hereditary 
hemochromatosis; inherited predisposition to blood clots (hereditary thrombofilia); hereditary 
breast and ovarian cancers; hereditary bowel cancer (familial adenomatous polyposis (FAP) 
and hereditary non-polyposis colon cancer (HNPCC); familial melanoma; rare syndromes 
e.g. multiple endocrine neoplasia (MEN), Von Hippel-Lindau syndrome; neurodegenerative 
conditions (spino-cerebellar ataxia; Huntington disease; early onset Alzheimer disease; 
motor neurone disease; prion disease); familial hyper-cholesterolaemia; familial hypertrophic 
cardiomyopathy; hereditary hypertension; hereditary emphysema (e.g.α-1 antitrypsin 
deficiency); adult polycystic kidney disease and ‘other’. Clinical services provided the 
research team with all mailed individuals’ gender, relevant genetic condition and year of birth 
for later comparison between those mailed and those who responded to the survey.  
Clinical services mailed all eligible individuals a research package that contained a cover 
letter about the research, a Participant Information Sheet, a questionnaire and a reply-paid 
envelope. Individuals received reminder packages approximately two weeks after initial mail 
out. Consent was implied by completion and return of questionnaires. Respondents could 
also volunteer their contact details on returned questionnaires for clarification of their survey 
responses and/or further follow-up.  
Questionnaires were developed by preliminary interviews and focus groups with consumers, 
advice from the GDP’s Expert Reference Group, and piloting. Explicit use of the term ‘genetic 
discrimination’ was avoided in the questionnaire so as to minimise bias (Geller et al. 2002; 
Treloar et al. 2004). The questionnaire comprised seven sections: genetic status and family 
history; genetic testing; perceptions and experiences regarding benefits and/or 
disadvantages associated with having genetic information; specific incidents of perceived 
disadvantage or unfair treatment; life insurance and employment information; attitudes 
towards genetic issues; and socio-demographic information. Respondents were asked to 
complete their questionnaires with regard to the genetic condition most relevant to them, 
which they specified from a list provided1.  
Where follow up contact details were provided by respondents, interviews were conducted by 
SDT as possible. The interviews varied in length from around 10 to 30 minutes and aimed to 
confirm and/or clarify respondents’ written responses regarding their experiences and 
perceptions.  
Data Analysis 
Survey data were analysed using the Statistical Package for the Social Sciences (SPSS) 
Version 12.0 (SPSS Inc. 2004). Basic descriptive statistical analyses were undertaken, 
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including frequencies, cross-tabulations and categorical association testing which was based 
on Pearson chi-square testing; where cell counts were less than 5, cross tabulations were 
based on empirical p-values and exact tests.   
Results 
From 2667 eligible individuals who were mailed questionnaires, 1185 respondents returned 
fully or partially completed questionnaires. Respondents from every Australian State and 
Territory were represented in the survey. The survey response rate was 51% after 319 
packages marked as ‘return to sender’ or reported inappropriate for inclusion in the study 
were deleted from the total responses.  
In keeping with the research focus of the study, stringent criteria were applied to the 
respondent sample regarding asymptomatic status. Eighty percent, or 951/1185 respondents 
met these criteria regarding asymptomatic status at the time of questionnaire completion. Of 
these, 96% (916/951) nominated one genetic condition regarding which they had a family 
history, a known genetic risk or a genetic test result. The most frequently nominated genetic 
conditions were Huntington disease (33%; n = 301), hereditary breast or ovarian cancer 
(31%; n = 280), hereditary bowel cancer (21%; n = 185) and hemochromatosis (5%; n = 45). 
For purposes of analysis, genetic conditions of relevance were organised into four groups: 
Group 1 neurodegenerative conditions (37%; n = 332), Group 2 familial cancers (53%; n = 
481), Group 3 hemochromatosis (5%; n = 45) and Group 4 ‘other’ genetic conditions (5%; 
n=46). Group 4 comprised a range of conditions that were substantively different in their 
characteristics, as a result of which results were often difficult to interpret; Group 4 results 
are therefore reported less frequently than results for other groups.  
Characteristics of the Sample 
The average age of respondents was 46 years, with 69% (n = 656) being female and 77% (n 
= 727) being married or partnered. Australia was the place of birth for 87% (n = 828) of 
respondents and 14 individuals (1.5%) identified as being of Aboriginal or Torres Strait 
Islander descent. Overall the sample was characterised by relatively high educational levels 
with almost half having diploma, bachelor or postgraduate qualifications. Almost two thirds of 
respondents reported that they were working full time at the time of the survey. At the time of 
the survey, 69% respondents held private health insurance and 41% held life insurance 
cover, compared with 49% and 33% respectively of the Australian population (Australian 
Institute of Health and Welfare (AIHW) 2004; Investment and Financial Services Association 
(IFSA) 2002).  
Ninety-five percent of survey respondents who answered the question regarding genetic 
testing (n = 729) reported having had a predictive genetic test3, with 2001 being the median 
year of testing. Thirty nine percent of respondents overall (n = 286) reported having received 
a positive test result, that is, a test result confirming the presence of the genetic mutation 
associated with the relevant genetic condition or disorder in their family; 55% (n = 399) 
reported having received a negative test result, that is, a test result confirming that the 
relevant mutation was not present; and 6% (n = 44) reported not having been tested or not 
having received their test result at the time of the survey. Figure 1 indicates the percentages 
of negative and positive test results for respondents according to genetic condition groupings 
of relevance.  The high proportion of test-positive respondents in relation to 
hemochromatosis was likely to be associated with recruitment from specialist a clinical 
research collection rather than a general clinical genetics service. 
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Figure 1.  Percentage of positive and negative genetic test 
results for respondents according to genetic condition 
groupings of relevance 
Perceived or Experienced Coercion to Undertake Genetic Testing 
Most respondents reported feeling no coercion or pressure to undertake a genetic test from 
the range of potential sources provided. Where reported, sources most frequently nominated 
from a given list were family members, doctors, geneticists/counsellors, life insurance 
companies and researchers; Table 1 provides further details. Genetic test result was not 
significantly associated with reporting of coercion.  
 
Table 1. Reported sources and amount of experienced 
coercion or pressure to undertake genetic testing. 
None Some A Lot Total Source of felt coercion
N % N % N %  
Family member 489 68 174 24 57 8 720 
Doctor 615 88 68 10 12 2 695 
Geneticist/counselor 622 89 65 10 9 1 696 
Insurance company 630 96 16 2 11 2 657 
Employer 649 99 7 1 2 0 658 
Bank/financial lender 653 99 4 1 2 0 659 
Researcher 637 96 23 4 3 0 663 
Other 537 96 13 3 7 1 557 
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The most frequently nominated ‘other source’ of coercion was ‘self’ (n=13), with respondents’ 
attached comments describing a sense of responsibility to undertake testing in order to 
clarify the genetic risks of significant others such as their children. There were no significant 
differences in experiences of coercion (‘none’, ‘some’, ‘a lot’) across the four groups for any 
sources apart from insurance companies ( = 24.8, P < .001) where higher than expected 
levels of coercion were reported by respondents for whom neurological conditions (Group 1, 
ND) were relevant. In this case, 22/27 (82%) of respondents who reported feeling ‘some’ or 
‘a lot’ of coercion were in Group 1 (ND), four were in Group 2 (familial cancers) and one was 
in Group 3 (hemochromatosis). 
2
6χ
Table 2 presents selected examples of interviewed cases reflecting perceptions and 
experiences in regard to coercion. Details of three respondents who had undergone 
presymptomatic testing for Huntington disease and who received a negative test result are 
provided.  
Table 2. Perceived or experienced coercion to undertake genetic testing. 
Personal 
Information 
 
Description of Experience 
 
Reported Impact 
Huntington disease 
Case A.  
Male aged 46 
years. No past or 
present health 
problems. 
Negative gene 
test. 
 
Applications for income protection insurance accepted 
with restrictions prior to negative test result. Required 
insurance as a business owner. Able to get insurance at 
standard rate after negative test result was sent to 
insurer. 
Felt coercion to have testing in 
order to secure insurance. 
Case B.  
Male aged 32 
years. No past or 
present health 
problems. 
Negative gene 
test. 
 
Respondent had superannuation but required income 
protection insurance. Application was accepted with 
significant loading prior to negative test result. Other 
companies had declined. Required insurance due to 
type of employment. Able to get insurance at standard 
rate only after his negative genetic test result was sent 
to insurer. 
Financial planner 
recommended the man 
undertake testing due to 
loading. 
Case C.  
Male aged 54 
years. Negative 
gene test. 
Respondent applied for life insurance as he established 
his own business after arriving in Australia. Insurer rang 
him to advise that he would have to be tested for HD 
(and demonstrate a gene negative result) if he wanted 
the insurance. Respondent thinking already of 
undertaking testing so as to be able to inform his 
children of their risk. 
 
Respondent reported coercion 
by insurer to undertake testing 
but also acknowledged family 
reasons for testing. 
Insurance  
Given its significance within the genetic discrimination context, one section of the 
questionnaire asked about respondent perceptions and experiences regarding life insurance. 
At the time of the survey, the types of insurance products held by respondents related to 
private health cover (69%), death (41%), accidental death (32%), mortgage (29%) and 
disability/income protection (24%). Significantly more than expected male respondents and 
fewer than expected females held life insurance ( = 4.4, P < .05), disability/income 
protection insurance ( 2 = 15.6, P < .001) and accidental death insuranc 21χ = 5.0, P < 
.05) at the time of the surve
2
1χ
1χ e (
y.  
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Respondents were asked about the importance of life insurance given their family history or 
genetic test information. On a scale from zero (very unimportant) to ten (very important), the 
median score of (720/951) respondents was seven. Of 668 respondents who perceived a 
need for life insurance in light of their family history or genetic test information, 79% (n=529) 
reported needing the same amount of insurance as they otherwise would have, 3% (n=17) 
needed less and 18% (n=121) needed more. Regarding the purchase of insurance products, 
94% (650/695) reported not purchasing more insurance than they would otherwise have, 6% 
(40/711) reported purchasing more and 1% (7/711) indicated they did not know. Three 
percent of question respondents (24/709) reported feeling the need to make multiple 
simultaneous applications in case of refusal. Two percent of question respondents reported 
that relatives had withheld family history information from them (13/711) and that they had 
withheld risk information from relatives (11/711), respectively, because of insurance 
concerns.  
Of 182 respondents who reported applying for life insurance products with knowledge of their 
level of risk, 146 respondents reported they were offered standard cover in all applications 
and 18 in some applications. Thirty-nine respondents reported being refused cover for one or 
more life insurance products, involving mostly death cover and income protection insurance 
(where specified). Types of non-standard cover, most frequently relating to life insurance and 
income protection, involved higher premiums (n=28), limited cover (n=17) and limited term 
cover (n=8). Type of cover offered did not differ significantly across the four groups or 
according to whether respondents were mutation positive or negative at the time of survey; 
respondents were also describing insurance cover that had been set in place prior to testing 
and therefore according to family history. Where reported, communication to respondents 
about non-standard cover was done verbally (31/61), in writing (19/73), directly from the 
company (23/69) or through an agent or broker (37/55). Twelve respondents reported having 
been asked to undertake predictive testing by a life insurance company, agent or broker, but 
there were no apparent differences between groups.  
Thirteen percent of question respondents reported ‘avoiding’ (92/710) or ‘giving up’ (93/711) 
applying for insurance because of fears of disclosing family risk information; 9% (62/713) had 
been advised not to bother applying because of the genetic condition in their family or their 
risk. When asked who had advised them, life insurance companies, agents or brokers 
(n=29); family members (n=16); genetic clinical advisors (n=7); friends (n=3); medical 
practitioners (n=1) and an accountant (n=1) were nominated. Group 1 (ND) respondents 
were significantly more likely, and Group 2 (FC) or 3 (HH) respondents less likely, to report 
avoiding applying for insurance ( = 12.1, P < .01), ‘giving up’ before applying ( = 13.1, P 
< .01) and being advised ‘not to bother’ applying for insurance ( = 19.7, P < .001). Seven 
percent of question respondents (47/703) had postponed testing in order to put desired life 
insurance into place first; where nominated, sources of advice to postpone were clinical 
genetics advisors (n=11), themselves i.e. it was a personal decision (n=9), family members 
(n=5) and medical practitioners (n=2).  
2
2χ 22χ
2
1χ
Several respondents provided accounts of their experiences regarding life insurance at follow 
up interview. Table 3 presents details of five cases involving genetic testing for the 
mutations(s) causing predisposition to bowel and several other cancers (HNPCC), breast 
and ovarian cancer and Huntington disease. With regard to the health insurance issue 
reported by Case A, health insurance is community-rated in Australia although waiting 
periods can be applied by insurers in regard to particular pre-existing illnesses. 
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Table 3.  Insurance issues 
Personal 
Information 
 
Description of Experience 
 
Reported Impact 
Hereditary non-polyposis colorectal cancer (HNPCC) 
Case D. 
Female aged 40 
years. No past or 
present health 
problems. Positive 
gene test HNPCC 
Respondent held trauma and income protection insurance with 
insurance company linked to employer’s superannuation 
policy. Respondent took voluntary redundancy (un-related to 
genetic test result) but felt forced to stay with insurance 
company linked to previous employer although this was not 
financially optimal for her. Respondent did not want to reveal 
her genetic test information to a new insurer.  In addition, when 
respondent applied for private health insurance, she was 
advised she would have a 12 month wait for coverage 
because of her ‘pre-existing condition’. Respondent sought 
advice from staff of genetics service who successfully 
advocated on her behalf; they argued that a positive genetic 
test result did not equate with having familial cancer. 
 
Respondent having regular 
bowel screening but anxious 
about future coverage by 
health insurer. She perceives 
she was limited in her choice 
of insurer which had financial 
implications. 
Case E. 
Male aged 28 years. 
No past or present 
health problems. 
Positive gene test 
HNPCC 
 
Respondent applied after testing through a broker for life 
insurance (death cover) and trauma insurance. Respondent 
declared family history and test result honestly and also noted 
he was having regular screening. He was offered death cover 
but denied trauma insurance. 
Self-employed; newly married and 
birth of first child occurred recently. 
Respondent was greatly 
concerned about providing for his 
family’s financial future. 
Huntington disease 
Case F. 
Female aged 36 
years. Tested for 
HD; waiting for 
result 
Respondent contacted broker to inquire about applying for life 
insurance; disclosed family history of mother’s recent HD 
diagnosis. Mother had long-standing diagnosis of 
schizophrenia and respondent had believed until recently that 
she was at risk of mental illness. Aunt had suicided but now 
believed to have had HD. Broker was unable to secure 
insurance and advised the respondent and her husband that it 
would be very difficult to secure insurance or to make any 
claim even if she was successful in gaining insurance. 
Respondent did not proceed with any applications. 
 
Respondent reported feeling 
‘very powerless and 
disheartened’; still in shock at 
being at risk for HD. Described 
the insurance experience as 
being the first indication that 
“life had changed, I am in a 
new space, I am vulnerable 
and discrimination is possible’. 
Case G. 
Female aged 51 
years. 
Intermediate range 
test result for HD5
Respondent undertook presymptomatic testing for HD and 
received an ‘intermediate’ test result5. She requested of her 
broker if she could apply for an increase in her life insurance 
policy. Broker said that he was aware of genetic conditions as 
he also had a family history of a genetic condition (not for HD) 
and advised her not to apply. Respondent understood that she 
was never likely to develop HD herself but did not challenge 
the broker’s advice. Respondent reported that her sister will 
not be tested because of insurance concerns and in order to 
protect her (sister’s) son, his privacy and his right to access 
insurance. 
 
Respondent accepted broker’s 
advice although she knew her 
situation was ‘more 
complicated than normal for 
Huntington’s disease’. 
Breast and ovarian cancer (BRCA1) 
Case H. 
Female aged 47 
years. Tested 
positive for 
BRCA1 gene 
Respondent had had life insurance for >10 years. She had 
purchased insurance policy in light of family history of breast 
cancer. She and husband had 4 children. Respondent 
regarded her insurance policy as ‘my gift to them if I died’. 
Respondent was subsequently tested and found to be positive 
for BRCA1 mutation. Later respondent lost her job in rural 
recession and could not afford to make premium payment on 
time; 10 days overdue. Insurer advised her that policy was 
cancelled. She and husband challenged the decision but 
insurer advised that although they would have liked to re-
instate her policy they could not in light of new information 
regarding genetic test result and she must re-apply. 
Respondent’s re-application for insurance was rejected. 
Respondent described the 
impact of this insurance 
experience as being 
significant: “I was angry and 
totally devastated’. 
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Employment 
Regarding employment, less than one third (n=135, 31%) of respondents to whom it applied 
reported that their employers were aware of their family history of the relevant genetic 
conditions or of their genetic risk in relation to such conditions. Few employers (n=12) or 
potential employers (n=9) had ever asked for such information. Of those who had asked for 
such information, three respondents nominated the Australian Defence Forces, one 
nominated both the Police Force and a medical practice, and three nominated pre-
employment medical assessments without specification.  
Several respondents described the consequences for them of employers knowing details of 
their genetic status including situations where sympathetic employers approved respondents’ 
requests to rearrange work schedules in order to undertake testing. Some respondents also 
described difficulties they had encountered in the employment area. Table 4 presents details 
of two cases which were related to Huntington disease testing.  
Table 4.  Employment issues 
Personal 
Information 
 
Description of Experience 
 
Reported Impact 
Huntington disease 
Case I.  
Female aged 44 
years. 
No symptoms. 
Negative gene test 
HD. 
Family history of HD and new diagnosis in family led to 
respondent seeking a predictive test. She was 
employed in service industry with significant 
responsibilities. When respondent ‘innocently’ 
requested time off for an appointment for the genetic 
test, employer immediately advised her to “step down 
and take time off” until the result was known. Employer 
also expressed concern about their own liability 
regarding employee’s continued performance in the 
public arena even though test result was unknown. 
Employer also requested the test result which 
respondent provided when her gene negative result 
became available. 
Respondent believed that as 
soon as her employer and co-
workers knew she was under-
taking a genetic test for HD, 
they assumed she had the 
condition and responded to her 
very differently than before 
they had this information, for 
example, constant surveillance 
and increased supervision of 
her work. Respondent was 
sole bread-winner for her 
family at the time. She found 
the genetic testing stressful 
and was simultaneously 
dealing with the implied threat 
of losing her employment; this 
had a significant negative 
impact on her and family. 
Respondent challenged the 
negative treatment however 
and reported that this resulted 
in greater education of her 
employer and co-workers re 
genetic issues. 
 
Case J.  
Female aged 45 
years. Currently 
well and self-
employed. Positive 
gene test HD. 
Termination of employment three months after 
disclosure of the test result to employer with rationale 
that the company was being restructured. Termination 
settlement was made with a non-disclosure clause.  
The respondent later learnt that the employer had 
informed colleagues that she had resigned due to a 
serious illness. 
Participant’s reaction to the 
test result led to short term 
depression.  Privacy and loss 
of employment due to mis-
understanding of meaning of 
test result. 
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Concerns about Life Insurance and Employment 
Respondents were asked if any concerns they had regarding the use of genetic information 
by third parties related more to employment, life insurance, both equally, neither or they 
could stipulate other concerns. Five percent nominated employment alone, 20% nominated 
insurance alone, 49% said they were equally important and 22% nominated neither as being 
important. Three percent nominated other concerns relating to privacy, confidentiality or 
personal ownership of genetic information (n=12); the need for family members to be aware 
(n=3); human rights (n=2); and discrimination (n=2).   
Discussion 
The Genetic Discrimination Project is the first comprehensive research program of its kind to 
be conducted in Australia. While concerns about, and accounts of alleged genetic 
discrimination have been reported in the Australian context, (ALRC/AHEC 2003; Barlow-
Stewart and Keays 2001; Otlowski 2002, 2001; Taylor 1998), there has been no 
comprehensive empirical research to date regarding the issue or its prevalence in Australia. 
While the Consumer sub-project of the GDP investigated clinical genetics services clients’ 
perceptions and experiences regarding various aspects of genetic discrimination, this paper 
reports perceptions and experiences regarding coercion to undertake predictive genetic 
testing and insurance and employment-related issues.   
The 51% response rate was comparable to other mail-based surveys in Australia (Brown et 
al. 2004; Sale et al. 2004; Steginga et al. 2001) and to a large UK study undertaken by Low 
and colleagues (1998) regarding genetic discrimination in life insurance. Greater participation 
by women in our survey (69% of the sample) is consistent not only with social science 
research generally (Broom 2002) but with genetics-related activity where Richards notes 
(1996 p. 258) ‘[I]n almost all aspects of genetics activity, it is the female members of a family 
who most often take the initiating role’. Richards (1996) describes women as most likely to 
adopt roles of ‘genetic housekeepers’ and ‘kin-keepers’ within families. Uptake of genetic 
testing for some conditions like mature-onset neurological conditions, carrier testing for cystic 
fibrosis and susceptibility testing for inherited cancer syndromes appears also to be at 
differentially greater rates by at-risk women compared with their male counterparts (Taylor 
2005). The relatively higher educational level of respondents is also consistent with findings 
of some studies relating to utilisation of genetic testing by people where HD is relevant 
(Meiser & Dunn 2000).  
Within our study, respondents overall reported no or little coercion to undertake predictive 
testing. Our sample comprised mainly individuals who undertook predictive testing however 
and their reported experiences of coercion may differ from people who chose not to 
undertake testing. Where reported, experiences of coercion included those where 
respondents believed external pressure had been applied to them to undertake predictive 
testing as well as those that reflected subjective feelings to undertake testing because of its 
availability or for other reasons (Geller et al. 2002; Petersen & Bunton 2002; Taylor 2004). 
Within family and healthcare contexts, individuals have reported a sense of coercion to 
undertake testing associated with their sense of responsibility and altruistic desire to help 
relatives like offspring determine their risks (Chapman 2002; Hallowell 1999; Taylor 2004) 
and to help others by participating in genetic research (Treloar et al. 2007). In our study, the 
most common sources of coercion where cited were family, doctors and 
geneticists/counsellors; this differed from the frequently expressed concern that third parties 
like life insurers or employers are most likely to be coercive (Otlowski 2005). The potential 
complexity and challenge for people in terms of family dynamics and relationships where 
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highly relevant genetic information is shared and where genetic test decisions and results 
can significantly impact on close others has been widely discussed (Chapman 2002; 
Chapman & Burn 1999; Cox & McKellin 1999; Geller et al. 2002; Hallowell 1999; Richards 
1996; Taylor 2004). How this might translate into experiences of coercion within the family 
context is largely under researched but respondents in our study certainly reported incidents 
of differential treatment and coercion within family contexts. How individuals and family 
members are managing and negotiating these challenges within the context of their shared 
genetic legacies and the family context merits further investigation.  
Clinical geneticists and counsellors were also a source of coercion reported by respondents 
in our study. Geller et al (2002) described instances where clinical professionals pressured 
people to undertake prenatal testing or advised them not to have children; similar incidents 
were reported in our study and were experienced as both highly coercive and distressing 
(Taylor et al. 2007, manuscript in review). The expression of such imperatives by well-
respected authority figures like clinical or medical professionals can represent and reinforce 
the social stigma that is experienced by many families with genetic conditions like HD (Cox & 
McKellin 1999; Taylor 2004). The potential for genetics clinicians to be ‘directive’ in their 
counselling and information-giving has also been widely discussed in the literature (Marteau 
& Richards 1996; Petersen & Bunton 2002). Where familial cancers are relevant, clinically-
based discussions about causative mutations in families and genetic testing may be more 
likely to occur in a shared family-based context (Chapman & Burn 1999; Haan 2003) 
compared with those regarding predictive testing for neurological conditions like HD where 
the focus may be more individualised and ‘private’ and primarily involve just the individual 
seeking testing plus a support person. The potential for differential treatment or 
discrimination exists for positive-testing individuals in relation to both types of conditions 
however (Bombard et al. 2007; Lynch et al. 2003; Markman 2004; Peterson et al. 2002). 
Whether some individuals could experience testing within the familial cancer context as 
potentially coercive due to authoritative clinical input or simply out of a sense of responsibility 
to family in that context is unknown. However, the principle of non-coercion remains central 
to best clinical genetics practice as does the responsibility of the clinician to ensure that the 
client’s decision to undertake predictive genetic testing for any disorder is underpinned by 
fully autonomous and well-informed consent (Haan 2003).  
While survey respondents also reported a relatively small amount of coercion in the 
insurance context, such experiences varied across groups. The significantly greater degree 
of insurer-based coercion that was reported by people where neurological conditions, mostly 
HD, were relevant is likely to reflect the historical position and long-standing experiences of 
such individuals regarding difficulty accessing life insurance products in Australia. Unlike 
people for whom conditions like familial cancers or hemochromatosis are relevant, 
individuals where HD is relevant have historically been denied access to life insurance 
products altogether in Australia, have had significant loadings imposed or been denied 
insurance even with exclusions (Otlowski et al. 2007a). Such underwriting decisions by life 
insurers appear legal at face value within the current context, based on an exemption 
granted to them under the Disability Discrimination Act (1992) (Ch) and provided such 
decisions can be substantiated actuarially. The actuarial justification in regard to the single-
gene, highly penetrant mutation for Huntington disease has generally been regarded as 
conclusive therefore (Otlowski et al. 2007a; Otlowski 2005) although assumptions about the 
lack of variability in HD for insurance-related underwriting have been challenged in recent 
times (Gutiérrez & MacDonald 2004; Otlowski et al. 2007a). The approach taken by the 
Australian life insurance sector is not the same for example as that in the United Kingdom 
where a positive test result or family history regarding HD does not necessarily result in the 
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outright denial of the life insurance application or the imposition of loadings or penalties. 
However, recommendations from the recent ALRC/AHEC Inquiry into the Protection of 
Human Genetic Information in Australia (ALRC/AHEC 2003) have included the need for 
insurers within the Australian context to improve their policies, practices and communications 
with consumers regarding insurance underwriting that utilises genetic information.  
People with family histories or positive genetic test information regarding HD have 
experienced insurance-related difficulties for over two decades in Australia as predictive 
genetic testing for HD, with its associated insurance implications, was the earliest predictive 
test for a mature-onset disorder to be offered in this country4 (Taylor 1994; Turner et al. 
1988). The challenges associated with accessing life insurance products for these individuals 
and families have therefore been cumulative over many years and have typically involved 
multiple family members and relatives. For such individuals, life insurance has realistically 
only been accessible to those who have agreed to undertake testing and  have been 
subsequently able to demonstrate a negative genetic test result to their insurer; those 
receiving a positive test result however become virtually uninsurable within the current 
Australian context. The cumulative experiences of families whose ‘uninsurable’ status is 
legally and socially affirmed through sanctioned insurance exemptions within anti-
discrimination legislation can reinforce the social stigma associated with such conditions. 
Under all of these circumstances, it may not be surprising that survey respondents where HD 
was relevant described feelings of ‘coercion’ associated with undertaking testing within the 
insurance context. Such a sense of coercion to test may be particularly pertinent where life 
insurance products are needed by people for purposes of business, self-employment or 
financial or mortgage borrowing.  
Although the nature of insurance-related experiences as reported by people for whom HD is 
a relevant genetic condition appeared to differ from other respondents, insurance was rated 
as an important issue by most respondents in the survey. As noted, unlike the United States, 
health insurance in Australia with regard to both the universal Medicare system and private 
health insurance, is community- rather than individually-rated and thus information about 
family history or genetic test information, as with all medical information, is not assessable for 
purposes of accessing either public or private health care services. Community-rated health 
insurance in Australia is also likely to significantly reduce the potential for genetic 
discrimination to occur in this country as health insurance has been a primary site for such 
discrimination in the United States (Otlowski et al. 2002). 
Given that gender has been shown to influence uptake of life insurance and associated 
products (Gandolfi & Miners 1996), reported uptake of life insurance, as well as the reporting 
of insurance-related concerns, may have been greater had there been more male survey 
respondents. The discrepancy between respondent and population rates in regard to life 
insurance could reflect either the increased importance of insurance to respondents or 
‘adverse selection’ where individuals with genetic information that is unavailable to insurers 
seek large amounts of life insurance (Otlowski et al. 2002). The potential for adverse 
selection to occur has been an issue of concern to life insurers. Respondents reported 
declaring their genetic risks honestly within the life insurance context however and almost all 
reported that they had not purchased more insurance products than they would otherwise 
have, given their family history or genetic test information; Zick et al (2000) found similarly. 
Several respondents reported that, on the advice of clinicians, they had organised life 
insurance prior to undertaking predictive testing or had submitted insurance applications 
simultaneously to maximise chances of success; Bombard et al. (2007) and Geller et al 
(1996) reported similarly. These options are consistent with current clinical policy and 
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practice guidelines in Australia and do not contravene applicants’ disclosure obligations to 
insurers provided relevant family history is disclosed (Centre for Genetics Education, 2003; 
Human Genetics Society of Australasia 1999).  
Some respondents, most likely those where neurological conditions like HD were relevant, 
also reported avoiding, giving up or being advised not to apply for life insurance, based on 
their or others’ beliefs that their applications would be unsuccessful. Similar strategies and 
self-protective behaviours used by people in order to pre-empt the risk that they will be 
differentially treated and/or to protect themselves from such risks have been reported in other 
studies (Bombard et al. 2007; Geller et al., 1996; Hall et al., 2005; Low et al., 1998). These 
experiences were reported by several respondents at interview as having significant impact 
or implications for them. Inexperienced individuals, advised by insurers, agents and brokers 
that their insurance applications will not succeed, and also likely to be aware that other family 
members have been unable to access insurance as in the case of HD, are unlikely to contest 
the advice. Low et al. (1998) questioned how well life insurance personnel like sales agents 
or brokers are informed about human genetics to be in a position to provide such preliminary 
risk assessments for potential life insurance applicants. Some respondents in our survey 
reported being advised at first point of inquiry by brokers and agents, as well as by insurers 
per se, that their applications would not succeed, resulting in an elimination of their 
applications prior to formal risk assessment. Life insurance under-writing decisions in 
applications involving genetic factors can vary across companies, even where the same 
genetic condition is relevant (Otlowski et al. 2007a; Gutiérrez & MacDonald 2004). Recently 
in Australia for example, some life insurers appear willing to be more flexible in their 
underwriting in regard to conditions like HD than has traditionally been done (Otlowski et al. 
2007a). The practices of front-line advisors in the life insurance sector where genetic factors 
appear relevant to applications seem worthy of attention. The elimination of insurance 
applications before they have been properly assessed, coupled with consumers who may be 
self-selecting out of insurance for self-protection and fear of negative treatment, are all likely 
to be impacting on life insurance sector reports in Australia that small numbers only of 
insurance applications have been unsuccessful because of genetic risk factors (Otlowski et 
al. 2007a).  
As noted above, the recent ALRC/AHEC Inquiry into the Protection of Human Genetic 
Information in Australia (ALRC/AHEC 2003) has resulted in recommendations to Australian 
life insurers to improve their policies, practices and communications with consumers 
regarding insurance underwriting that utilises genetic information. All consumers are entitled 
to submit applications for life insurance products, to have them assessed accurately and to 
be advised of the reasons for special conditions or denial of insurance as well as their right to 
appeal such decisions. The potential support of clinical genetics specialists in support of life 
insurance applications where genetic factors are involved is also worthy of widespread 
promotion to the general community, the clinical genetics community and through networks 
of genetic support groups (Otlowski et al. 2007a).   
Regarding employment, also a central issue when analysing genetic discrimination 
(ALRC/AHEC 2003; Geller et al. 1996; Knoppers et al. 2004; Low et al. 1998; Otlowski et al. 
2002), a small number only of respondents reported that employers or potential employers 
had requested genetic information or that it was required in pre-employment medical 
assessments; where mentioned, public rather than private sector employers were nominated. 
The benefits for several respondents of employers knowing genetic information were also 
noted. The lack of employers’ use of genetic information reported in the survey concurs with 
findings from the recent national inquiry (ALRC/AHEC 2003) which concluded that Australian 
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employers were not seeking, or using, genetic information for employment-related purposes 
on any large scale, in spite of it being currently not illegal for them to do so. However several 
respondents did report accounts of employment-related experiences at follow up interview. 
The ALRC/AHEC (2003) has recommended that employers should not be permitted to 
collect or use genetic information regarding workers or potential workers except where it 
specifically relates to health and safety). Survey respondents also expressed equal concern 
about both employers and insurers having legally-sanctioned access to genetic information; 
such attitudes are consistent with those of the broader Australian community (Barlow-Stewart 
et al. 2005). 
It should be noted that there were several limitations in our study. Findings are based on 
cross-sectional data and self-reported perceptions and experiences relating to a specified 
time period, that is pre-2003 Australian context. The asymptomatic status of respondents 
was not able to be independently verified although the sample was based on most recent 
clinical assessment of asymptomatic status by genetics clinicians and rigorous exclusion 
criteria were applied to the data prior to its analysis. Sampling through clinical genetics 
services in Australia is likely to have resulted in respondents who were positively oriented 
towards predictive genetic testing and who had other characteristics that are unlikely to be 
representative of the broader at risk populations. The survey questionnaire was also quite 
complex and there was some evidence that non-specific wording and use of the term ‘risk’ 
may have resulted in individuals with negative test results self-selecting out of the study or a 
section of the questionnaire because they erroneously believed it did not apply to them. 
Finally, while the term ‘genetic discrimination’ was not explicitly used in the questionnaire in 
order to minimise bias, its inclusion in the approach letter and information sheet might have 
had an unknown effect on response. 
Conclusion 
The perceptions and experiences of Australian consumers constitute a significant 
perspective regarding the complex phenomenon of genetic discrimination or negative 
treatment based on genetic information acquired from family history or genetic testing. The 
full public and preventive health benefits associated with the increasing availability of genetic 
testing will not be fully realised unless individuals can freely engage with genetic testing 
without fear of negative treatment as a result of it. Individuals and families are now reporting 
experiences of both coercion and negative treatment and are developing strategies to 
minimise or pre-empt anticipated occurrences. Coercion to undertake testing can occur 
subtly within a range of contexts including family, health, clinical genetics, and insurance and 
employment contexts. The potential impact on individuals and families of coercion as well as 
post-test negative treatment is substantial. It is imperative that the community and all 
relevant sectors be informed about these issues, that individuals are not openly or covertly 
coerced into undertaking genetic testing and that the potential for negative treatment in 
contexts like insurance and employment is monitored and pro-actively addressed.  
Endnotes 
1 For detailed information about genetic conditions, modes of inheritance, treatment and 
genetic testing, see the website of The Centre for Genetics Education: 
http://www.genetics.com.au
2 GDP website www.gdproject.org  
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3 Missing data were high on this question because some respondents, mostly those with a 
negative test result, may have misinterpreted an instruction in this section of the 
questionnaire and mistakenly skipped several questions 
4 Predictive testing for Huntington disease was first offered in Australia in the mid 1980s, 
significantly earlier than for many other conditions regarding which testing has more recently 
become available  
5 A small percentage of test results for Huntington Disease cannot be interpreted with 
certainty; such test results are described as being in the ‘intermediate’ range rather than 
represent a definitive result. Individuals receiving intermediate test results are unlikely to ever 
develop symptoms of HD themselves but their children may face an increased risk 
(Langbehn et al. 2004).   
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